Agios has launched a new website called Drive PK trial, which offers patients, caregivers, and healthcare professionals information about their phase 2 clinical trial for the oral medication, AG-348. This medicine has been developed as a potential treatment for pyruvate kinase deficiency. Due to a deficiency in the enzyme, pyruvate kinase, people with pk deficiency are anemic, which means they have a reduced number of healthy red blood cells. The study is being conducted to determine whether AG-348 increases the levels of healthy red blood cells in the body. At this time trial locations are open at Boston Children’s Hospital in Boston, MA and at Stanford University in Palo Alto, CA. New site locations will continue to be added. To learn more about this study visit Agios’ new Drive PK Trial website.